Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for AAA Growth Inhibition
NCT04224051Phase 2Enrolling by invitation
- Sponsor
- Akademiska sjukhuset
- Start
- Feb 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in abdominal aortic aneurysm (AAA) (2 arms), sponsored by Akademiska sjukhuset. Primary endpoint: Abdominal aortic aneurysm diameter growth rate at 5 years. Started Feb 2020; status: enrolling by invitation.
02
Drugs
metformin
03
Conditions
abdominal aortic aneurysm (AAA)
Beyond the preview
Go deeper on NCT04224051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224051.